Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan

Neurology

Volumn 89, Issue 11, 2017, Pages 1127-1134

  Suzuki, Shigeaki ^a   Ishikawa, Nobuhisa ^b   Konoeda, Fumie ^c   Seki, Nobuhiko ^d   Fukushima, Satoshi ^e   Takahashi, Kikuko ^f   Uhara, Hisashi ^g   Hasegawa, Yoshikazu ^h   Inomata, Shinichiro ⁱ   Otani, Yasushi ^j   Yokota, Kenji ^k   Hirose, Takashi ^l   Tanaka, Ryo ^m   Suzuki, Norihiro ^a   Matsui, Makoto ⁿ  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

^c SAISEIKAI CENTRAL HOSPITAL   (Japan)

^d TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

^f HAKODATE CENTRAL GENERAL HOSPITAL   (Japan)

^g SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Izumi Municipal Hospital   (Japan)

ⁱ Sapporo Kosei General Hospital   (Japan)

^j TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^k NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l NIPPON MEDICAL SCHOOL TAMA NAGAYAMA HOSPITAL   (Japan)

^m KAWASAKI MEDICAL SCHOOL   (Japan)

ⁿ Kanazawa Medical University   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; CREATINE KINASE; IPILIMUMAB; NIVOLUMAB; ANTINEOPLASTIC AGENT; AUTOANTIBODY; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DAILY LIFE ACTIVITY; DETERIORATION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYASTHENIA GRAVIS; MYOCARDITIS; MYOSITIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DRUG DATABASE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; BIOMARKERS; CREATINE KINASE; DATABASES, PHARMACEUTICAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; MYOCARDITIS; MYOSITIS; NEOPLASMS; TREATMENT OUTCOME;

EID: 85030612370     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000004359     Document Type: Article

References (26)

1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56-61.
2. Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016;29:806-812.
3. Johnson DB, Saranga-Perry V, Lavin PJ, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 2015;33:e122-e124.
4. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:210-225.
5. Lau KH, Kumar A, Yang IH, Nowak RJ. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve 2016;54:157-161.
6. Zhu J, Li Y. Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve 2016;54:506-507.
7. Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 2015;52:307-308.
8. Nguyen BH, Kuo J, Budiman A, Christie H, Ali S. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res 2017;27:152-154.
9. Polat P, Donofrio PD. Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle Nerve 2016;54:507.
10. Sciacca G, Nicoletti A, Rampello L, Noto L, Parra HJ, Zappia M. Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve 2016;54:507-509.
11. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015;14:1023-1036.
12. Jaretzki A III, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards: task force of the medical scientific advisory board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
14. Maeda O, Yokota K, Atsuta N, Katsuno M, Akiyama M, Ando Y. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci 2016;78:119-122.
15. Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 2016;46:86-88.
16. Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 2016;107:1055-1058.
17. Tanaka R, Sunada Y, Fujimoto W. Successful reinstitution of nivolumab in combination with corticosteroids for metastatic malignant melanoma with myasthenia gravis as an immune-related adverse event. Kawasaki Med J 2017;43: 59-61.
18. Konoeda F, Suzuki S, Nishimoto Y,HoshinoH, Takagi M. A case of myasthenia gravis and myositis induced by nivolumab. Rinsho Shinkeigaku (Clin Neurol) 2017;57:373-377.
19. Fukazawa Y, Natsume M, Sakamoto M, et al. A case of nivolumab-induced myocarditis concomitant with myasthenia gravis. Presented at the 177th Kanto Regional Meeting of the Japan Lung Cancer Society; November 26, 2016; Tokyo.
20. Barrons RW. Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy 1997;17:1220-1232.
21. Suzuki S, Tanaka K, Yasuoka H, Fukuuchi Y, Kawakami Y, Kuwana M. Autoreactive T cells to the P3A1 isoform of AChR alpha subunit in myasthenia gravis. J Neuroimmunol 2003;137:177-186.
22. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-384.
23. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749-1755.
24. Suzuki S, Utsugisawa K, Yoshikawa H, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 2009;66:1334-1338.
25. Suzuki S, Utsugisawa K, Suzuki N. Overlooked nonmotor symptoms in myasthenia gravis. J Neurol Neurosurg Psychiatry 2013;84:989-994.
26. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated antistriated muscle antibody. J Immunother Cancer 2016;4:36.